Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report

被引：4

作者：

Zhou, Huamiao ^{[1
]}

Xu, Binyue ^{[2
]}

Xu, Jili ^{[2
]}

Zhu, Guomeng ^{[1
]}

Guo, Yong ^{[1
]}

机构：

[1] Zhejiang Prov Hosp Tradit Chinese Med, Dept Oncol, Hangzhou, Peoples R China

[2] Zhejiang Chinese Med Univ, Sch Clin Med 1, Hangzhou, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

基金：

中国国家自然科学基金;

关键词：

NSCLC; MRPS9-ALK; NGS; crizotinib; ALK-TKI; ANAPLASTIC LYMPHOMA KINASE; FRAMESHIFT MUTATION; EGFR-TKI; ALK; CANCER; IMMUNOHISTOCHEMISTRY; ALECTINIB; EFFICACY; NSCLC; GENE;

D O I：

10.3389/fonc.2021.670907

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5-6% of non-small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine kinase inhibitors (ALK-TKIs) (crizotinib then alectinib), as her imaging findings and clinical symptoms significantly improved. At last follow-up, over 21 months of overall survival (OS) has been achieved since ALK-TKI treatment. The progression-free survival (PFS) is already ten months since alectinib. The adverse effects were manageable. The case presented here provides first clinical evidence of the efficacy of ALK-TKIs in NSCLC patients with MRPS9-ALK fusion.

引用

页数：7

共 45 条

[1] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (vol 368, pg 2385, 2013) [J].

不详 .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (16) :1582-1582

[2] Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells [J].

Armstrong, F ;

Duplantier, MM ;

Trempat, P ;

Hieblot, C ;

Lamant, L ;

Espinos, E ;

Racaud-Sultan, C ;

Allouche, M ;

Campo, E ;

Delsol, G ;

Touriol, C .

ONCOGENE, 2004, 23 (36) :6071-6082

[3] Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib [J].

Chen, Yao ;

Zhang, Xiaochen ;

Jiang, Qi ;

Wang, Bo ;

Wang, Yina ;

Yan Junrong .

LUNG CANCER, 2020, 146 :370-372

[4] ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties [J].

Childress, Merrida A. ;

Himmelberg, Stephen M. ;

Chen, Huiqin ;

Deng, Wanleng ;

Davies, Michael A. ;

Lovly, Christine M. .

MOLECULAR CANCER RESEARCH, 2018, 16 (11) :1724-1736

[5] Molecular Modeling of ALK L1198F and/or G1202R Mutations to Determine Differential Crizotinib Sensitivity [J].

Chuang, Yu-Chung ;

Huang, Bo-Yen ;

Chang, Hsin-Wen ;

Yang, Chia-Ning .

SCIENTIFIC REPORTS, 2019, 9 (1)

[6] Challenges in ALK inhibition of ALK-positive non-small-cell lung cancer: from ALK positivity detection to treatment strategies after relapse [J].

Cortinovis, Diego ;

Canova, Stefania ;

Abbate, Maria I. ;

Colonese, Francesca ;

Cogliati, Viola ;

Bidoli, Paolo .

FUTURE ONCOLOGY, 2018, 14 (22) :2303-2317

[7] Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics? [J].

Dagogo-Jack, Ibiayi ;

Shaw, Alice T. .

ONCOLOGIST, 2016, 21 (06) :662-663

[8] Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer [J].

Doebele, Robert C. ;

Pilling, Amanda B. ;

Aisner, Dara L. ;

Kutateladze, Tatiana G. ;

Le, Anh T. ;

Weickhardt, Andrew J. ;

Kondo, Kimi L. ;

Linderman, Derek J. ;

Heasley, Lynn E. ;

Franklin, Wilbur A. ;

Varella-Garcia, Marileila ;

Camidge, D. Ross .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1472-1482

[9] CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib [J].

Du, Xue ;

Shao, Yun ;

Gao, Hongjun ;

Zhang, Xueli ;

Zhang, Han ;

Ban, Yi ;

Qin, Haifeng ;

Tai, Yanhong .

CANCER BIOLOGY & THERAPY, 2018, 19 (11) :962-966

[10] Translocations involving anaplastic lymphoma kinase (ALK) [J].

Duyster, J ;

Bai, RY ;

Morris, SW .

ONCOGENE, 2001, 20 (40) :5623-5637

← 1 2 3 4 5 →